Quince Therapeutics stock (US74833Q1004): Analysts see 345% upside potential

Quince Therapeutics (QNCX) shares carry an average analyst price target of $7.25, implying 344.79% upside from recent levels of $1.63, based on four brokerage reports as of July 8, 2025.

Quince Therapeutics, Inc. (QNCX) has drawn attention from analysts, with an average price target of $7.25 based on short-term forecasts from four analysts, representing a potential 344.79% increase from the last closing price of $1.63. The targets range from $4.00 to $10.00, according to data updated on Zacks as of Jul 8, 2025. The stock traded at $1.65 on that date, up 1.23%.

As of: 14.05.2026

By the editorial team – specialized in equity coverage.

At a glance

• Name: Quince Therapeutics, Inc.
• Sector/industry: Biotechnology
• Headquarters/country: United States
• Core markets: Neurodegenerative diseases
• Key revenue drivers: RNA therapeutics pipeline
• Home exchange/listing venue: Nasdaq (QNCX)
• Trading currency: USD

Quince Therapeutics: core business model

Quince Therapeutics is a clinical-stage biotechnology company focused on developing RNA-based therapeutics for neurodegenerative diseases and multiple sclerosis. The firm accelerates investments in innovative therapies targeting these disorders, aiming to address unmet medical needs through advanced molecular approaches. Its pipeline emphasizes precision medicine for conditions affecting the central nervous system.

Main revenue and product drivers for Quince Therapeutics

Quince Therapeutics derives potential value from its RNA therapeutics platform, which targets key pathways in neurodegenerative disorders. Early-stage programs focus on multiple sclerosis and related conditions, with investments ramping up to advance clinical trials. Future revenue hinges on successful trial outcomes, regulatory approvals, and partnerships in the biotech sector.

Industry trends and competitive position

The neurodegenerative disease therapeutics market is expanding rapidly, driven by aging populations and demand for effective treatments. Quince Therapeutics positions itself in RNA-based innovations, competing with larger players in gene therapy and precision medicine. US investors track such firms for exposure to high-growth biotech segments amid rising healthcare spending.

Why Quince Therapeutics matters for US investors

Listed on Nasdaq, Quince Therapeutics offers US investors direct access to cutting-edge biotech innovations in neurodegenerative treatments. With the US market leading in clinical trials and funding for such therapies, the company's progress resonates with portfolios focused on healthcare growth stocks.

Conclusion

Quince Therapeutics continues to advance its RNA therapeutics pipeline amid analyst optimism reflected in substantial upside targets. Market dynamics in neurodegenerative treatments provide context for its development efforts. Investors monitor clinical milestones and sector trends for ongoing developments.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.